A RANDOMIZED, PHASE II TRIAL OF DOCETAXEL WITH OR WITHOUT PX-866, AN IRREVERSIBLE ORAL PHOSPHATIDYLINOSITOL 3-KINASE INHIBITOR, IN PATIENTS WITH RELAPSED OR METASTATIC NON-SMALL-CELL LUNG CANCER